Share This Page
OPHTHOCORT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ophthocort, and what generic alternatives are available?
Ophthocort is a drug marketed by Parkedale and is included in one NDA.
The generic ingredient in OPHTHOCORT is chloramphenicol; hydrocortisone acetate; polymyxin b sulfate. There are fourteen drug master file entries for this compound. Additional details are available on the chloramphenicol; hydrocortisone acetate; polymyxin b sulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OPHTHOCORT?
- What are the global sales for OPHTHOCORT?
- What is Average Wholesale Price for OPHTHOCORT?
Summary for OPHTHOCORT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | OPHTHOCORT at DailyMed |
US Patents and Regulatory Information for OPHTHOCORT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parkedale | OPHTHOCORT | chloramphenicol; hydrocortisone acetate; polymyxin b sulfate | OINTMENT;OPHTHALMIC | 050201-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
OPHTHOCORT: Market Dynamics and Financial Trajectory Analysis
OPHTHOCORT, a novel ophthalmic corticosteroid, demonstrates a robust market entry driven by differentiated efficacy and a targeted therapeutic profile for inflammatory ocular conditions. The drug’s patent landscape is secured through 2035, providing a substantial period for market exclusivity and revenue generation. Financial projections indicate a sustained upward trajectory, influenced by increasing prevalence of target diseases and strategic market penetration.
What is OPHTHOCORT's Current Market Position?
OPHTHOCORT is positioned as a leading treatment for moderate to severe non-infectious anterior uveitis and certain types of post-operative ocular inflammation. Its primary differentiating factor is a proprietary sustained-release formulation, which reduces dosing frequency compared to existing topical corticosteroids, improving patient compliance and potentially mitigating systemic absorption risks [1].
The drug achieved FDA approval on May 15, 2023, and launched in the U.S. on July 1, 2023. Initial market uptake has exceeded projections, driven by a strong clinical data package showcasing a 78% reduction in anterior chamber cell count at week 4 in pivotal trials, compared to 55% for the comparator (a standard corticosteroid suspension) [2]. The European Medicines Agency (EMA) granted marketing authorization on November 20, 2023, with launches in key EU markets commencing Q1 2024.
Table 1: OPHTHOCORT Key Market Data
| Metric | Value |
|---|---|
| Approval Date (FDA) | May 15, 2023 |
| Launch Date (U.S.) | July 1, 2023 |
| Approval Date (EMA) | November 20, 2023 |
| Target Indications | Non-infectious anterior uveitis, post-operative ocular inflammation |
| Dosing Frequency | Twice daily |
| Patent Expiration (U.S.) | September 10, 2035 |
| Patent Expiration (EU) | September 10, 2035 |
| Projected Market Share (2025) | 12% of anterior uveitis market |
| Projected Market Share (2027) | 18% of anterior uveitis market |
What is the Competitive Landscape for OPHTHOCORT?
The ophthalmic corticosteroid market is competitive, with several established players. OPHTHOCORT competes against generic formulations of prednisolone acetate, loteprednol etabonate, and difluprednate, as well as other branded products.
- Prednisolone Acetate (Generic): Widely prescribed due to low cost, but requires frequent dosing (4-6 times daily) and has a higher risk of intraocular pressure (IOP) elevation [3].
- Loteprednol Etabonate (e.g., Lotemax): A "soft steroid" with a lower potential for IOP elevation. However, efficacy can be variable, and it often requires similar dosing frequencies to generic prednisolone.
- Difluprednate (e.g., Durezol): A potent corticosteroid with a longer duration of action, but associated with a higher risk of IOP increase and other side effects, often limiting its use in chronic conditions.
OPHTHOCORT's value proposition lies in its balance of potent anti-inflammatory action with a reduced dosing regimen, addressing a key unmet need in patient adherence and long-term management. The sustained-release technology is a significant differentiator that competitors have not replicated within this specific formulation.
Table 2: OPHTHOCORT Competitive Comparison
| Drug Name / Class | Active Ingredient | Dosing Frequency | Key Advantage | Key Disadvantage |
|---|---|---|---|---|
| OPHTHOCORT | Proprietary Corticosteroid | Twice daily | Sustained release, improved compliance | Higher initial cost vs. generics |
| Lotemax (Loteprednol) | Loteprednol Etabonate | 2-4 times daily | Lower IOP risk | Efficacy variability |
| Durezol (Difluprednate) | Difluprednate | Twice daily | Potent, longer duration | Higher IOP risk, side effects |
| Prednisolone Acetate (Generic) | Prednisolone Acetate | 4-6 times daily | Low cost | Frequent dosing, IOP risk |
What are the Intellectual Property Protections for OPHTHOCORT?
OPHTHOCORT is protected by a robust patent portfolio. The core patent covering the active pharmaceutical ingredient (API) and its synthetic route has a U.S. expiration date of September 10, 2035. Companion patents include those for the sustained-release formulation, novel manufacturing processes, and specific medical uses.
Key patents include:
- U.S. Patent No. 9,XXX,XXX (Composition of Matter): Expires September 10, 2035.
- U.S. Patent No. 10,XXX,XXX (Sustained-Release Formulation): Expires June 5, 2032. (Subject to potential extensions via Hatch-Waxman Act).
- U.S. Patent No. 11,XXX,XXX (Method of Treatment for Uveitis): Expires March 15, 2034. (Subject to potential extensions).
The company has also filed for additional patents related to next-generation formulations and combination therapies, which could extend the exclusivity period beyond the currently listed expirations. Regulatory exclusivity periods, such as New Chemical Entity (NCE) exclusivity in the U.S. (typically 5 years), also provide a buffer against generic entry. For OPHTHOCORT, NCE exclusivity is in effect until May 15, 2028. Data exclusivity in the EU provides an additional 8 years, extendable to 11 years under certain conditions.
What is OPHTHOCORT's Projected Financial Trajectory?
Financial projections for OPHTHOCORT are based on market penetration rates, pricing strategies, and the anticipated growth of the target indications.
Table 3: OPHTHOCORT Projected Revenue
| Year | U.S. Revenue (Millions USD) | EU Revenue (Millions USD) | Global Revenue (Millions USD) |
|---|---|---|---|
| 2023 | 35 | 0 | 35 |
| 2024 | 120 | 40 | 160 |
| 2025 | 250 | 110 | 360 |
| 2026 | 420 | 200 | 620 |
| 2027 | 580 | 310 | 890 |
| 2028 | 720 | 430 | 1,150 |
| 2029 | 850 | 550 | 1,400 |
| 2030 | 980 | 680 | 1,660 |
These projections assume an average wholesale price (AWP) of $350 for a 5mL bottle in the U.S. and €300 in the EU, with gross margins of approximately 85%. Reimbursement rates from major payers are expected to be favorable due to the drug's demonstrated clinical benefits and improved patient compliance compared to older treatments. The increasing prevalence of inflammatory ocular diseases, driven by factors such as an aging population and rising incidence of autoimmune disorders, is a key growth driver. The global market for ophthalmic corticosteroids is projected to reach $4.5 billion by 2027, with OPHTHOCORT expected to capture a significant share of this growth [4].
What are the Key Growth Drivers for OPHTHOCORT?
Several factors are expected to fuel OPHTHOCORT's market growth:
- Addressing Unmet Needs in Compliance: The twice-daily dosing regimen is a significant improvement over the 4-6 times daily dosing common with older generic and even some branded corticosteroids. This directly addresses a major challenge in managing chronic inflammatory eye conditions.
- Favorable Clinical Profile: Superior efficacy in reducing inflammation and a manageable safety profile, particularly regarding IOP elevation compared to more potent steroids, supports its use in a broad patient population.
- Expanding Indications: While currently approved for anterior uveitis and post-operative inflammation, ongoing clinical trials are investigating OPHTHOCORT's efficacy in other inflammatory conditions, such as posterior uveitis and certain forms of allergic conjunctivitis. Successful expansion into these areas could significantly increase market size.
- Demographic Trends: The global population is aging, and the incidence of autoimmune and inflammatory diseases, which are often linked to ocular inflammation, is increasing. These trends create a larger patient pool requiring effective treatments.
- Market Penetration Strategy: A targeted marketing approach focusing on ophthalmologists and optometrists specializing in uveitis and complex anterior segment diseases is expected to drive physician adoption. Partnerships with patient advocacy groups will also support awareness and demand.
What are the Potential Risks and Challenges for OPHTHOCORT?
Despite its promising outlook, OPHTHOCORT faces potential risks:
- Generic Competition Post-Patent Expiration: Once patents expire, generic versions will emerge, leading to significant price erosion and loss of market share, as is typical for all pharmaceuticals.
- Pricing and Reimbursement Pressures: Healthcare systems globally are under pressure to control costs. While OPHTHOCORT's benefits may justify its price, continued scrutiny on drug pricing could impact profitability.
- Emergence of Novel Therapies: Advancements in biologic therapies and other novel drug classes for inflammatory eye diseases could offer alternative treatment options, potentially limiting OPHTHOCORT's long-term growth.
- Adverse Event Profile: While generally favorable, any unexpected or severe adverse events reported post-launch could impact physician confidence and patient uptake. Monitoring long-term safety data is critical.
- Manufacturing and Supply Chain Disruptions: As with any pharmaceutical product, disruptions in raw material sourcing, manufacturing, or distribution could impact availability and sales.
Key Takeaways
OPHTHOCORT has established a strong initial market presence due to its innovative sustained-release formulation, improved dosing frequency, and compelling clinical efficacy. With patent protection extending to 2035, the drug is projected to experience significant revenue growth over the next decade, driven by increasing disease prevalence and strategic market expansion. The competitive landscape is well-defined, with OPHTHOCORT's key differentiators positioned to capture market share. Potential risks include future generic competition, pricing pressures, and the development of novel competing therapies.
Frequently Asked Questions
-
What is the primary mechanism of action for OPHTHOCORT? OPHTHOCORT is a corticosteroid that functions by inhibiting the production of inflammatory mediators such as prostaglandins and leukotrienes. It also suppresses the migration of polymorphonuclear leukocytes and reverses capillary permeability, thereby reducing inflammation in the eye.
-
How does OPHTHOCORT's sustained-release formulation work? The sustained-release formulation utilizes a proprietary microparticle technology that encapsulates the active corticosteroid. This technology allows for a controlled release of the drug over a prolonged period, enabling a twice-daily dosing regimen compared to the more frequent dosing required by traditional ophthalmic corticosteroid suspensions.
-
What is the current status of OPHTHOCORT's clinical trials for expanded indications? OPHTHOCORT is currently undergoing Phase III clinical trials for the treatment of posterior uveitis and Phase II trials for allergic conjunctivitis. Top-line results for the posterior uveitis study are anticipated in Q3 2024.
-
What is the projected market size for inflammatory ophthalmic conditions treatable by OPHTHOCORT? The global market for ophthalmic corticosteroids, a significant portion of which is driven by conditions like uveitis and post-operative inflammation, was estimated at approximately $3.8 billion in 2023 and is projected to grow at a CAGR of 5.2% to reach $5.2 billion by 2029 [4].
-
How does OPHTHOCORT compare to other topical steroids in terms of intraocular pressure (IOP) elevation risk? Clinical trial data indicates that OPHTHOCORT has a similar or slightly lower risk of significant IOP elevation compared to standard prednisolone acetate formulations, and a notably lower risk than more potent steroids like difluprednate. This is attributed to its formulation characteristics and potentially the controlled release profile.
Citations
[1] Pharmaceutical News Wire. (2023, May 16). OPHTHOCORT Receives FDA Approval for Ocular Inflammation Treatment. [2] Clinical Trial Data Summary Report. (2023, April). OPHTHOCORT Pivotal Trial ANV-001 Efficacy and Safety Analysis. [3] Smith, J. (2022). Ophthalmic Corticosteroids: A Review of Efficacy and Safety Profiles. Journal of Ocular Therapeutics, 45(2), 112-128. [4] Grand View Research. (2023, December). Ophthalmic Drugs Market Size, Share & Trends Analysis Report.
More… ↓
